Abstract Background/Purpose: Aminoglycosides possess in vitro activity against aerobic and facultative Gram-negative bacilli. However, nationwide surveillance on susceptibility data of Acinetobacter baumannii complex and Pseudomonas aeruginosa to aminoglycosides was limited, and aminoglycoside resistance has emerged in the past decade. We study the in vitro susceptibility of A. baumannii complex and other nonfermentative Gram-negative bacilli (NFGNB) to aminoglycosides. Methods: A total of 378 NFGNB blood isolates causing healthcare-associated bloodstream infections during 2008 and 2013 at four medical centers in Taiwan were tested for their susceptibilities to four aminoglycosides using the agar dilution method (gentamicin, amikacin, tobramycin, and isepamicin) and disc diffusion method (isepamicin). 
Introduction
Nonfermentative Gram-negative bacilli (NFGNB) are the leading pathogens that cause nosocomial bacteremia and infections. 1 They result in high fatality in critically ill patients and in patients with septic shock and bacteremia. The mortality rate attributed to NFGNB bacteremia could be as high as 25%. 2, 3 Among NFGNB, Pseudomonas aeruginosa, Acinetobacter baumannii complex, and Stenotrophomonas maltophilia were the most common pathogens causing healthcare-associated bloodstream infections. 3 NFGNB are easily resistant to most of the beta-lactam antibiotics through beta-lactamase production, impermeability, and multidrug efflux pumps. 4 The emerging resistance of NFGNB to all commonly used antibiotics may lead to inappropriate administration of empirical antibiotics, which contributes to the high fatality rate of NFGNB bacteremia. 2, 5, 6 The limitation of the susceptible antibiotic spectrum also makes the clinical treatment more difficult. Therefore, periodic active surveillance for the epidemiology of NFGNB resistance is crucial for infection control and antibiotic stewardship.
Aminoglycosides possess in vitro activity against many aerobic and facultative Gram-negative bacilli, like P. aeruginosa and Acinetobacter spp., and they are intrinsically inactive against some NFGNB, such as S. maltophilia and Burkholderia cepacia complex. Therefore, the aminoglycosides are the drug of choice for antimicrobial combination for severe infections (e.g., bacteremia) caused by NFGNB. 7 However, resistance to aminoglycosides in P. aeruginosa and Acinetobacter spp. can develop by enzymatic modification, impermeability, or MexXY (also referred to as AmrAB) efflux pumps. 6, 8 The susceptibility data of NFGNB to aminoglycosides were limited in Taiwan, and the previous study did not differentiate A. baumannii complex into the species level for investigation. 9 In this study, we aimed to compare the in vitro susceptibility of NFGNB blood isolates to aminoglycosides in patients with healthcareassociated bacteremia in Taiwan.
Methods

Bacterial isolates
Healthcare-associated bloodstream infections were defined as bacteremia occurring in patients admitted over 48 hours, in patients with recent hospitalization history within 90 days, in patients who were nursing home residents, and in patients who were frequent visitors of the hemodialysis facility or the hospital-based clinic. Blood isolates of NFGNB collected during 2008 to 2013 and preserved at four medical centers in Taiwan were retrospectively recruited using their collection numbers from the laboratory. The four hospitals included National Taiwan University Hospital (NTUH) and Taipei Veterans General Hospital (TVGH) located in northern Taiwan; China Medical University Hospital (CMUH) located in central Taiwan; and Kaohsiung Chang Gung Memorial Hospital (KCGMH) located in southern Taiwan. A total of 378 available NFGNB isolates (NTUH, 319 isolates; TVGH, 18 isolates; CMUH, 32 isolates; and KCGMH, 9 isolates) retrospectively identified from 2013 isolates were randomly selected by the collection numbers for aminoglycoside susceptibility testing. Those isolates included P. aeruginosa (100 isolates), A. baumannii (76 isolates), Acinetobacter nosocomialis (54 isolates), Acinetobacter pittii (45 isolates), S. maltophilia (50 isolates), and B. cepacia complex (53 isolates). None of the patients had duplicate bacterial isolates in this study.
Bacterial identification
The species of all isolates, including A. baumannii complex strains, were routinely identified using standard conventional microbiological methods or by the Vitek System (bioMérieux, Hazelwood, MO, USA) as required. The genospecies of A. baumannii strains were further identified according to the sequence of the 16S-23S rRNA gene intergenic spacer region as previously described. 10 
Antimicrobial susceptibility testing
Gentamicin supplied by Schering Plough (Bloomfield, NJ, USA), amikacin by Bristol-Myers Squibb (Princeton, NJ, USA), tobramycin by Eli Lilly (Indianapolis, IN, USA), and isepamicin by TTY Biopharm (Taipei, Taiwan) were used for susceptibility testing using the agar dilution method.
The minimal inhibitory concentration (MIC) for each aminoglycoside to the isolated bacteria was determined using the agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) standard procedure protocol. The susceptibility to gentamicin, amikacin, and tobramycin was also determined according to the MIC interpretive criteria suggested by CLSI. 11 Given that there is no consensus susceptibility criteria for isepamicin, the same MIC interpretive criteria for amikacin was applied to isepamicin as follows: susceptible, 16 mg/mL; intermediate, 32 mg/mL; resistant, 64 mg/mL. Because there is no consensus clinical breakpoint for S. maltophilia and B. cepacia complex either, the same susceptibility criteria for P. aeruginosa was applied for these two clinical species as follows: (for gentamicin, tobramycin) susceptible, 4 mg/ mL; intermediate, 8 mg/mL; resistant, 16 mg/mL; (for amikacin) susceptible, 16 mg/mL; intermediate, 32 mg/ mL; resistant, 64 mg/mL. The disk diffusion test to isepamicin for the isolated bacteria was also performed according to CLSI standard protocol 12 The zone diameter interpretive criteria for amikacin were applied for the isepamicin because of the same reason: susceptible, 17 mm; intermediate, 15e16 mm; resistant, 14 mm. Escherichia coli American Type Culture Collection (ATCC; Rockville, MD, USA) 25922 and P. aeruginosa ATCC 27853 were used for daily quality control testing as recommended by the CLSI.
Statistical analysis
Susceptibility data were classified as dichotomous outcomes, which were compared using chi-square statistics, and p < 0.05 was defined as statistically significant. For comparisons between multiple groups, the logistic regression model was used. Data were analyzed using Stata software, version 12 (StataCorp, College Station, TX, USA).
Results
In vitro susceptibility of NFGNB to aminoglycosides using the agar dilution method
In vitro susceptibilities of the 378 blood isolates of NFGNB to aminoglycosides were determined according to MIC using the agar dilution method (Table 1) . Three species in A. baumannii complex have different susceptibility profiles to aminoglycosides. A. baumannii was highly resistant to all four aminoglycosides. However, >80% of A. nosocomialis isolates and A. pittii isolates were susceptible to amikacin, tobramycin, and isepamicin, but not to gentamicin. Among the tested aminoglycosides, amikacin possessed the best in vitro activity against both A. nosocomialis (susceptibility: 96%, MIC 90 : 8 mg/mL) and A. pittii (susceptibility: 91%, MIC 90 : 16 mg/mL). Tobramycin had similar high activity to isepamicin against A. nosocomialis (susceptibility: 92% vs. 96%, respectively; and MIC 90 : 4 mg/mL and 8 mg/mL, respectively), however, their activities against A. pittii were moderate (susceptibility: 80% for both; and MIC 90 : 8 mg/mL and 32 mg/mL, respectively). Gentamicin had poor activity against the current A. baumannii complex. The differences in susceptibility rates to the four aminoglycosides between A. baumannii and A. nosocomialis, A. baumannii and A. pittii, and among the three A. baumannii complex strains were all statistically significant (p < 0.001).
All four aminoglycosides still had good activity against current P. aeruginosa blood isolates from patients with healthcare-associated bloodstream infections in Taiwan. The susceptibility rates of the P. aeruginosa isolates to isepamicin, amikacin, tobramycin, and gentamicin were 99%, 98%, 98%, and 94%, respectively. The MIC 90 values of isepamicin, amikacin, tobramycin, and gentamicin for the P. aeruginosa isolates were 8 mg/mL, 4 mg/mL, 1 mg/mL, and 4 mg/mL, respectively.
Both the S. maltophilia and B. cepacia complex isolates were intrinsically resistant to all four aminoglycosides. The susceptible rates of S. maltophilia isolates to aminoglycosides varied from 4% to 10% with all the MIC 90 values being >128 mg/mL. The susceptible rates of B. cepacia complex isolates varied from 4% to 8% with all the MIC 90 values being >128 mg/mL.
Comparing the activities of the four aminoglycosides against the 378 NFGNB isolates from patients with healthcare-associated bloodstream infections in Taiwan, amikacin possessed the greatest activity against P. aeruginosa (susceptibility: 98%), A. nosocomialis (susceptibility: 96%), and A. pittii (susceptibility: 91%), but poor activity against A. baumannii (susceptible: 4%), S. maltophilia (susceptible: 4%), and B. cepacia complex (susceptible: 6%); tobramycin and isepamicin had lesser activity against A. pittii (susceptibility: 80% for both aminoglycosides) compared to amikacin. Among all NFGNB isolates in this study, only P. aeruginosa was still highly susceptible to all four aminoglycosides.
In vitro susceptibility of NFGNB to isepamicin by the disc diffusion method
Zone diameter results and the susceptibility rates of NFGNB isolates to isepamicin using the disc diffusion method are listed in Table 2 . Isepamicin possessed good activity against A. nosocomialis (susceptibility: 94%) and P. aeruginosa (susceptibility: 99%), but had poor activity against A. baumannii (susceptible: 4%), S. maltophilia (susceptible: 26%), and B. cepacia complex (susceptible: 17%); these results were similar to those by the agar dilution method. However, the susceptibility rate of A. pittii to isepamicin was better using the disc diffusion method than by using the agar dilution method (the susceptibility was 91% in the disk diffusion method and 80% in the agar dilution method). The differences in the susceptibility rates to isepamicin using the disc diffusion method between A. baumannii and A. nosocomialis, A. baumannii and A. pittii, and among the three A. baumannii complex strains were all statistically significant (p < 0.001). Except for S. maltophilia Table 2 In vitro susceptibility of blood isolates of nonfermentative Gram-negative bacilli (NFGNB) to isepamicin using the disc diffusion method and the agar dilution method. (p Z 0.037), there were no discrepancies of antimicrobial susceptibilities of aminoglycosides against other NFGNB blood isolates between the agar dilution method and the disc diffusion method (all p > 0.05). There was high categorical agreement between the susceptibility rates determined using the disc diffusion method and the agar dilution method (Pearson correlation coefficient r Z 0.9887, p Z 0.0002).
Discussion
Our study demonstrated different in vitro susceptibilities to aminoglycosides among genospecies of A. baumannii complex. In addition, P. aeruginosa isolates from nosocomial bacteremia in Taiwan remained highly susceptible to aminoglycosides. Finally, amikacin possessed the widest spectrum coverage among the four aminoglycosides against NFGNB, including P. aeruginosa, A. nosocomialis, and A. pittii.
A. baumannii complex comprises Acinetobacter genospecies 1 (A. calcoaceticus), genospecies 2 (A. baumannii), genospecies 3 (A. pittii), and genospecies 13TU (A. nosocomialis). They are phenotypically similar and the commercial identification system has limited capacity to differentiate between them. 13, 14 Compared to A. nosocomialis and A. pittii, A. baumannii had higher carbapenem resistance and corresponded to higher attributable mortality of the patients with A. baumannii bacteremia. Most of the studies showed high resistant rates of A. baumannii to gentamicin, amikacin, tobramycin, and isepamicin. 14,15,17e19 However, susceptibilities of A. nosocomialis and A. pittii to aminoglycosides were not consistent between studies, with the susceptibility rates varied from 22% to 80.6% for A. nosocomialis and 25% to 66.7% for A. pittii.
14, 15 The sample sizes of the blood isolates of A. nosocomialis and A. pittii in those studies were limited, especially in data from Taiwan. 9,14e18 None of the previous studies provided the susceptibility of A. nosocomialis and A. pittii to isepamicin. Our study revealed that both isepamicin and amikacin produced similar activities against A. baumannii complex. Consistent with these studies, 9,14e18 our results showed high resistance of A. baumannii to all four aminoglycosides in patients with nosocomial A. baumannii bacteremia in Taiwan. Nevertheless, aminoglycosides, except gentamicin, still possessed good activity against A. nosocomialis and A. pittii in nosocomial bacteremic patients (>80% isolates were susceptible), especially for amikacin (96% of the A. nosocomialis isolates and 91% of the A. pittii isolates were susceptible to amikacin). These results implied the importance of genospecies differentiation of the A. baumannii complex for clinical treatment guidance.
P. aeruginosa was the leading NFGNB that caused nosocomial NFGNB bacteremia. 3, 20 Increasing prevalence of multidrug resistant P. aeruginosa even worsened the clinical treatment, with increased mortality rate in bacteremic patients. 4,8,21e24 Chromosomally encoding both RmtD methylase and metallo-b-lactamases genes have also been found leading to pan-drug resistant P. aeruginosa. 25, 26 Few antibiotics were available and were susceptible to P. aeruginosa when it was resistant to beta-lactam antibiotics due to cross-resistance. Compared to carbapenems and quinolones, aminoglycosides have the lowest crossresistance and coresistance rates for piperacillin-resistant P. aeruginosa. 5, 21 Our current study showed high susceptibility of P. aeruginosa to all aminoglycosides in nosocomial bacteremic patients in Taiwan. However, several studies have shown increasing resistance of gentamicin and tobramycin with resistant rates around 15e30% in P. aeruginosa isolates in Taiwan. 9, 25 Overall, amikacin and probably isepamicin, remained active for P. aeruginosa, however, emerging multidrug resistance to aminoglycosides should be monitored regularly and intensively.
All four aminoglycosides had poor activity against S. maltophilia and B. cepacia complex isolates in our study, which was consistent with the previous study and our knowledge. 9 In addition, most of the NFGNB from patients with nosocomial NFGNB bacteremia in Taiwan were resistant to gentamicin. Given that other studies revealed increasing resistance to gentamicin in P. aeruginosa isolates, gentamicin should not be administered alone empirically for NFGNB infection in Taiwan before the drug susceptibility is available. Among the four aminoglycosides we tested in our study, amikacin had the broadest spectrum coverage against NFGNB, including P. aeruginosa (susceptibility: 98%), A. nosocomialis (susceptibility: 96%), and A. pittii (susceptibility: 91%).
There are limitations to the current study. Firstly, we identified patients with healthcare-associated bloodstream infections and randomly selected from the available preserved blood isolates for aminoglycoside susceptibility testing due to the limitation of faculties. The true disease burden of each NFGNB therefore could not be assessed. Secondly, we only did the susceptibility testing to aminoglycosides without investigating the susceptibility profiles of other antibiotics and the possible resistant mechanisms to aminoglycosides. Therefore, the relationships of crossresistance or coresistance of aminoglycosides with other antimicrobial agents were unknown. Finally, no clinical or treatment data of patients were extracted in our study. The in vitro susceptibility to aminoglycosides may not be fully translated into the clinical treatment response in vivo.
In summary, genospecies of A. baumannii complex possessed heterogeneous susceptibility to aminoglycosides. Amikacin had the greatest in vitro activity against P. aeruginosa, A. nosocomialis, and A. pittii, whereas tobramycin and isepamicin were less potent against A. pittii. Further in vivo clinical data and continuous resistance monitoring will be warranted to establish clinical recommendations for aminoglycosides treatment against NFGNB in patients with healthcare-associated bloodstream infections in Taiwan.
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